Last 12 months
Inside the activity.
0 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 29, 2020 Filed Nov 2, 2020 20:13 UTC |
Bushman Julie LDirector
|
GrantCommon Stock | 391 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-006488 · primarydocument.xml · nonDerivative · entry 1 Bushman Julie L · CIK 0001518599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 480 Read SEC document |
| October 05, 2020 Filed Nov 6, 2020 21:47 UTC |
Hippel JamesChief Financial Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 8,809 | $0.00 Strike: $108.49 | $0.00 |
DisclosureSEC source: 0001562180-20-006582 · primarydocument.xml · derivative · entry 18 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,809 shares Expires 2022-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F15 · derivative.exercise_date: Fully exercisable. Read SEC document |
| August 09, 2020 Filed Aug 11, 2020 22:22 UTC |
Furlow Brenda S.SVP - General Counsel
|
Exercise / conversionRestricted Stock Units · Derivative | 1,724 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-20-000292 · edgar.xml · derivative · entry 6 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,724 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F4 · derivative.exercise_date: On 8/9/2020, the Board of Directors certified vesting of 1,724 performance RSUs. F4 · derivative.expiration_date: On 8/9/2020, the Board of Directors certified vesting of 1,724 performance RSUs. Read SEC document |
| August 09, 2020 Filed Aug 11, 2020 22:22 UTC |
Furlow Brenda S.SVP - General Counsel
|
Tax withholdingCommon Stock | 849 | $265.76 | $225,630.24 |
DisclosureSEC source: 0000914190-20-000292 · edgar.xml · nonDerivative · entry 2 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,186 Read SEC document |
| August 09, 2020 Filed Aug 11, 2020 22:22 UTC |
Furlow Brenda S.SVP - General Counsel
|
Exercise / conversionCommon Stock | 1,724 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-20-000292 · edgar.xml · nonDerivative · entry 1 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,035 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2020 Filed Aug 11, 2020 22:21 UTC |
Hippel JamesChief Financial Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 4,438 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-20-000290 · edgar.xml · derivative · entry 6 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,438 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F4 · derivative.exercise_date: On 8/9/2020, the Board of Directors certified vesting of 4,438 performance RSUs. F4 · derivative.expiration_date: On 8/9/2020, the Board of Directors certified vesting of 4,438 performance RSUs. Read SEC document |
| August 09, 2020 Filed Aug 11, 2020 22:21 UTC |
Hippel JamesChief Financial Officer
|
Tax withholdingCommon Stock | 2,184 | $265.76 | $580,419.84 |
DisclosureSEC source: 0000914190-20-000290 · edgar.xml · nonDerivative · entry 2 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,137 Read SEC document |
| August 09, 2020 Filed Aug 11, 2020 22:21 UTC |
Hippel JamesChief Financial Officer
|
Exercise / conversionCommon Stock | 4,438 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-20-000290 · edgar.xml · nonDerivative · entry 1 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,321 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2020 Filed Aug 11, 2020 22:21 UTC |
Eansor Norman DavidPresident-Protein Sciences
|
Exercise / conversionRestricted Stock Units · Derivative | 2,174 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-20-000291 · edgar.xml · derivative · entry 3 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,174 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F2 · derivative.exercise_date: On 8/9/2020, the Board of Directors certified vesting of 2,174 performance RSUs. F2 · derivative.expiration_date: On 8/9/2020, the Board of Directors certified vesting of 2,174 performance RSUs. Read SEC document |
| August 09, 2020 Filed Aug 11, 2020 22:21 UTC |
Eansor Norman DavidPresident-Protein Sciences
|
Tax withholdingCommon Stock | 856 | $265.76 | $227,490.56 |
DisclosureSEC source: 0000914190-20-000291 · edgar.xml · nonDerivative · entry 2 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,318 Read SEC document |
| August 09, 2020 Filed Aug 11, 2020 22:21 UTC |
Eansor Norman DavidPresident-Protein Sciences
|
Exercise / conversionCommon Stock | 2,174 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-20-000291 · edgar.xml · nonDerivative · entry 1 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,174 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2020 Filed Aug 11, 2020 22:20 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 21,291 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-20-000289 · edgar.xml · derivative · entry 11 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,291 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F5 · derivative.exercise_date: On 8/9/2020, the Board of Directors certified vesting of 21,291 performance RSUs. F5 · derivative.expiration_date: On 8/9/2020, the Board of Directors certified vesting of 21,291 performance RSUs. Read SEC document |
| August 09, 2020 Filed Aug 11, 2020 22:20 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
Tax withholdingCommon Stock | 12,287 | $265.76 | $3,265,393.12 |
DisclosureSEC source: 0000914190-20-000289 · edgar.xml · nonDerivative · entry 2 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,487 F1 · balance_after: Includes (i) 3,759 shares of restricted stock for which the risk of forfeiture will lapse on August 8, 2021; (ii) 7,527 shares of restricted stock for which the risk of forfeiture will lapse with respect to 3,764 shares on August 7, 2021 and as to 3,763 shares on August 7, 2022; and (iii) 8,586 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2021, August 5, 2022 and August 5, 2023. Read SEC document |
| August 09, 2020 Filed Aug 11, 2020 22:20 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
Exercise / conversionCommon Stock | 21,291 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-20-000289 · edgar.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,774 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes (i) 3,759 shares of restricted stock for which the risk of forfeiture will lapse on August 8, 2021; (ii) 7,527 shares of restricted stock for which the risk of forfeiture will lapse with respect to 3,764 shares on August 7, 2021 and as to 3,763 shares on August 7, 2022; and (iii) 8,586 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2021, August 5, 2022 and August 5, 2023. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 23:07 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
GrantStock Options (Right to Buy) · Derivative | 16,650 | $0.00 Strike: $267.87 | $0.00 |
DisclosureSEC source: 0000914190-20-000253 · edgar.xml · derivative · entry 23 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,650 Underlying: Common Stock · 16,650 shares Expires 2027-08-05 F14 · derivative.exercise_date: Options to purchase 5,550 shares vest on each of 8/5/21, 8/5/22 and 8/5/23. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 23:07 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
GrantStock Options (Right to Buy) · Derivative | 16,650 | $0.00 Strike: $267.87 | $0.00 |
DisclosureSEC source: 0000914190-20-000253 · edgar.xml · derivative · entry 22 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,650 Underlying: Common Stock · 16,650 shares Expires 2027-08-05 F13 · derivative.exercise_date: Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021 Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 23:07 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
GrantStock Options (Right to Buy) · Derivative | 38,295 | $0.00 Strike: $267.87 | $0.00 |
DisclosureSEC source: 0000914190-20-000253 · edgar.xml · derivative · entry 21 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,295 Underlying: Common Stock · 38,295 shares Expires 2027-08-05 F12 · derivative.exercise_date: Options to purchase 9,574 shares vest on each of 8/5/21, 8/5/22 and 8/5/23 and options to purchase 9,573 shares vest on 8/5/24. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 23:07 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
GrantStock Options (Right to Buy) · Derivative | 57,442 | $0.00 Strike: $267.87 | $0.00 |
DisclosureSEC source: 0000914190-20-000253 · edgar.xml · derivative · entry 20 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,442 Underlying: Common Stock · 57,442 shares Expires 2027-08-05 F11 · derivative.exercise_date: Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 23:07 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
GrantRestricted Stock Units · Derivative | 12,879 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-20-000253 · edgar.xml · derivative · entry 19 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,879 Underlying: Common Stock · 12,879 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F11 · derivative.exercise_date: Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F11 · derivative.expiration_date: Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 23:07 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
GrantCommon Stock | 8,586 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-20-000253 · edgar.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,483 F1 · balance_after: Includes (i) 4,732 shares of restricted stock for which the risk of forfeiture will lapse on August 9, 2020; (ii) 7,519 shares of restricted stock for which the risk of forfeiture will lapse as to 3,760 shares on August 8, 2020 and as to 3,759 shares on August 8, 2021; (iii) 7,527 shares of restricted stock for which the risk of forfeiture will lapse with respect to 3,764 shares on August 7, 2021 and as to 3,763 shares on August 7, 2022; and (iv) 8,586 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2021, August 5, 2022 and August 5, 2023. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 22:58 UTC |
Kelderman KimPres. Diagnostics & Genom
|
GrantStock Options (Right to Buy) · Derivative | 8,325 | $0.00 Strike: $267.87 | $0.00 |
DisclosureSEC source: 0000914190-20-000251 · edgar.xml · derivative · entry 15 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,325 Underlying: Common Stock · 8,325 shares Expires 2027-08-05 F12 · derivative.exercise_date: Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021 Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 22:58 UTC |
Kelderman KimPres. Diagnostics & Genom
|
GrantStock Options (Right to Buy) · Derivative | 8,325 | $0.00 Strike: $267.87 | $0.00 |
DisclosureSEC source: 0000914190-20-000251 · edgar.xml · derivative · entry 14 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,325 Underlying: Common Stock · 8,325 shares Expires 2027-08-05 F11 · derivative.exercise_date: Options to purchase 2,775 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 22:58 UTC |
Kelderman KimPres. Diagnostics & Genom
|
GrantStock Options (Right to Buy) · Derivative | 11,988 | $0.00 Strike: $267.87 | $0.00 |
DisclosureSEC source: 0000914190-20-000251 · edgar.xml · derivative · entry 13 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,988 Underlying: Common Stock · 11,988 shares Expires 2027-08-05 F10 · derivative.exercise_date: Options to purchase 2,997 shares vest on each of 8/5/2021, 8/5/2022, 8/5/2023 and 8/5/2024. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 22:58 UTC |
Kelderman KimPres. Diagnostics & Genom
|
GrantStock Options (Right to Buy) · Derivative | 8,991 | $0.00 Strike: $267.87 | $0.00 |
DisclosureSEC source: 0000914190-20-000251 · edgar.xml · derivative · entry 12 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,991 Underlying: Common Stock · 8,991 shares Expires 2027-08-05 F9 · derivative.exercise_date: Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 22:58 UTC |
Kelderman KimPres. Diagnostics & Genom
|
GrantRestricted Stock Units · Derivative | 2,015 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-20-000251 · edgar.xml · derivative · entry 11 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,015 Underlying: Common Stock · 2,015 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F9 · derivative.exercise_date: Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F9 · derivative.expiration_date: Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 22:50 UTC |
Hippel JamesChief Financial Officer
|
GrantStock Options (Right to Buy) · Derivative | 8,325 | $0.00 Strike: $267.87 | $0.00 |
DisclosureSEC source: 0000914190-20-000249 · edgar.xml · derivative · entry 18 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,325 Underlying: Common Stock · 8,325 shares Expires 2027-08-05 F14 · derivative.exercise_date: Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021 Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 22:50 UTC |
Hippel JamesChief Financial Officer
|
GrantStock Options (Right to Buy) · Derivative | 8,325 | $0.00 Strike: $267.87 | $0.00 |
DisclosureSEC source: 0000914190-20-000249 · edgar.xml · derivative · entry 17 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,325 Underlying: Common Stock · 8,325 shares Expires 2027-08-05 F13 · derivative.exercise_date: Options to purchase 2,775 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 22:50 UTC |
Hippel JamesChief Financial Officer
|
GrantStock Options (Right to Buy) · Derivative | 19,147 | $0.00 Strike: $267.87 | $0.00 |
DisclosureSEC source: 0000914190-20-000249 · edgar.xml · derivative · entry 16 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,147 Underlying: Common Stock · 19,147 shares Expires 2027-08-05 F12 · derivative.exercise_date: Options to purchase 4,787 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023 and options to purchase 4,786 shares vest on 8/5/2024. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 22:50 UTC |
Hippel JamesChief Financial Officer
|
GrantStock Options (Right to Buy) · Derivative | 14,360 | $0.00 Strike: $267.87 | $0.00 |
DisclosureSEC source: 0000914190-20-000249 · edgar.xml · derivative · entry 15 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,360 Underlying: Common Stock · 14,360 shares Expires 2027-08-05 F11 · derivative.exercise_date: Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 22:50 UTC |
Hippel JamesChief Financial Officer
|
GrantRestricted Stock Units · Derivative | 3,219 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-20-000249 · edgar.xml · derivative · entry 14 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,219 Underlying: Common Stock · 3,219 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F11 · derivative.exercise_date: Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F11 · derivative.expiration_date: Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 22:40 UTC |
Furlow Brenda S.SVP - General Counsel
|
GrantStock Options (Right to Buy) · Derivative | 8,325 | $0.00 Strike: $267.87 | $0.00 |
DisclosureSEC source: 0000914190-20-000247 · edgar.xml · derivative · entry 18 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,325 Underlying: Common Stock · 8,325 shares Expires 2027-08-05 F13 · derivative.exercise_date: Options to purchase 2,775 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 22:40 UTC |
Furlow Brenda S.SVP - General Counsel
|
GrantStock Options (Right to Buy) · Derivative | 8,325 | $0.00 Strike: $267.87 | $0.00 |
DisclosureSEC source: 0000914190-20-000247 · edgar.xml · derivative · entry 17 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,325 Underlying: Common Stock · 8,325 shares Expires 2027-08-05 F12 · derivative.exercise_date: Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021 Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 22:40 UTC |
Furlow Brenda S.SVP - General Counsel
|
GrantStock Options (Right to Buy) · Derivative | 9,990 | $0.00 Strike: $267.87 | $0.00 |
DisclosureSEC source: 0000914190-20-000247 · edgar.xml · derivative · entry 16 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,990 Underlying: Common Stock · 9,990 shares Expires 2027-08-05 F11 · derivative.exercise_date: Options to purchase 2,498 shares vest on each of 8/5/2021 and 8/5/2022 and options to purchase 2,497 shares vest on each of 8/5/2023 and 8/5/2024. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 22:40 UTC |
Furlow Brenda S.SVP - General Counsel
|
GrantStock Options (Right to Buy) · Derivative | 7,492 | $0.00 Strike: $267.87 | $0.00 |
DisclosureSEC source: 0000914190-20-000247 · edgar.xml · derivative · entry 15 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,492 Underlying: Common Stock · 7,492 shares Expires 2027-08-05 F10 · derivative.exercise_date: Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 22:40 UTC |
Furlow Brenda S.SVP - General Counsel
|
GrantRestricted Stock Units · Derivative | 1,679 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-20-000247 · edgar.xml · derivative · entry 14 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,679 Underlying: Common Stock · 1,679 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F10 · derivative.exercise_date: Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F10 · derivative.expiration_date: Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 22:33 UTC |
Eansor Norman DavidPresident-Protein Sciences
|
GrantStock Options (Right to Buy) · Derivative | 24,975 | $0.00 Strike: $267.87 | $0.00 |
DisclosureSEC source: 0000914190-20-000245 · edgar.xml · derivative · entry 16 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,975 Underlying: Common Stock · 24,975 shares Expires 2027-08-05 F13 · derivative.exercise_date: Options to purchase 8,325 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 22:33 UTC |
Eansor Norman DavidPresident-Protein Sciences
|
GrantStock Options (Right to Buy) · Derivative | 24,975 | $0.00 Strike: $267.87 | $0.00 |
DisclosureSEC source: 0000914190-20-000245 · edgar.xml · derivative · entry 15 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,975 Underlying: Common Stock · 24,975 shares Expires 2027-08-05 F12 · derivative.exercise_date: Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021 Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 22:33 UTC |
Eansor Norman DavidPresident-Protein Sciences
|
GrantStock Options (Right to Buy) · Derivative | 15,318 | $0.00 Strike: $267.87 | $0.00 |
DisclosureSEC source: 0000914190-20-000245 · edgar.xml · derivative · entry 14 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,318 Underlying: Common Stock · 15,318 shares Expires 2027-08-05 F11 · derivative.exercise_date: Options to purchase 3,830 shares vest on each of 8/5/2021 and 8/5/2022 and options to purchase 3,829 shares vest on each of 8/5/2023 and 8/5/2024. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 22:33 UTC |
Eansor Norman DavidPresident-Protein Sciences
|
GrantStock Options (Right to Buy) · Derivative | 11,488 | $0.00 Strike: $267.87 | $0.00 |
DisclosureSEC source: 0000914190-20-000245 · edgar.xml · derivative · entry 13 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,488 Underlying: Common Stock · 11,488 shares Expires 2027-08-05 F10 · derivative.exercise_date: Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 22:33 UTC |
Eansor Norman DavidPresident-Protein Sciences
|
GrantRestricted Stock Units · Derivative | 2,575 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-20-000245 · edgar.xml · derivative · entry 12 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,575 Underlying: Common Stock · 2,575 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F10 · derivative.exercise_date: Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F10 · derivative.expiration_date: Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 21:19 UTC |
Bushman Julie LDirector
|
GrantStock Option (Right to Buy) · Derivative | 361 | $0.00 Strike: $278.87 | $0.00 |
DisclosureSEC source: 0001562180-20-005331 · primarydocument.xml · derivative · entry 2 Bushman Julie L · CIK 0001518599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 361 Underlying: Common Stock · 361 shares Expires 2030-07-31 Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 21:19 UTC |
Bushman Julie LDirector
|
GrantCommon Stock | 89 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-005331 · primarydocument.xml · nonDerivative · entry 1 Bushman Julie L · CIK 0001518599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89 Read SEC document |
| July 09, 2020 Filed Jul 13, 2020 20:02 UTC |
Furlow Brenda S.SVP - General Counsel
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 9,079 | $0.00 Strike: $108.49 | $0.00 |
DisclosureSEC source: 0001562180-20-005109 · primarydocument.xml · derivative · entry 10 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 921 Underlying: Common Stock · 9,079 shares Expires 2022-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Vests 2,500 share(s) on 07-Aug-2016, 2,500 share(s) on 07-Aug-2017, 2,500 share(s) on 07-Aug-2018, 1,579 share(s) on 07-Aug-2019 Read SEC document |
| July 09, 2020 Filed Jul 13, 2020 20:02 UTC |
Furlow Brenda S.SVP - General Counsel
|
SaleCommon Stock | 74 | $278.84 | $20,634.16 |
DisclosureSEC source: 0001562180-20-005109 · primarydocument.xml · nonDerivative · entry 9 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,311 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2020. Read SEC document |
| July 09, 2020 Filed Jul 13, 2020 20:02 UTC |
Furlow Brenda S.SVP - General Counsel
|
SaleCommon Stock | 2,746 | $278.06 | $763,555.51 |
DisclosureSEC source: 0001562180-20-005109 · primarydocument.xml · nonDerivative · entry 8 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,385 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2020. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $277.7700 to $278.6600, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 09, 2020 Filed Jul 13, 2020 20:02 UTC |
Furlow Brenda S.SVP - General Counsel
|
SaleCommon Stock | 1,954 | $277.28 | $541,812.15 |
DisclosureSEC source: 0001562180-20-005109 · primarydocument.xml · nonDerivative · entry 7 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,131 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2020. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $276.6500 to $277.6200, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 09, 2020 Filed Jul 13, 2020 20:02 UTC |
Furlow Brenda S.SVP - General Counsel
|
SaleCommon Stock | 400 | $276.03 | $110,410.00 |
DisclosureSEC source: 0001562180-20-005109 · primarydocument.xml · nonDerivative · entry 6 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,085 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2020. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $275.4000 to $276.3500, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 09, 2020 Filed Jul 13, 2020 20:02 UTC |
Furlow Brenda S.SVP - General Counsel
|
SaleCommon Stock | 918 | $274.80 | $252,270.81 |
DisclosureSEC source: 0001562180-20-005109 · primarydocument.xml · nonDerivative · entry 5 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,485 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2020. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $274.3100 to $275.2100, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 09, 2020 Filed Jul 13, 2020 20:02 UTC |
Furlow Brenda S.SVP - General Counsel
|
SaleCommon Stock | 2,042 | $273.33 | $558,143.33 |
DisclosureSEC source: 0001562180-20-005109 · primarydocument.xml · nonDerivative · entry 4 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,403 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $272.8500 to $273.7900, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 09, 2020 Filed Jul 13, 2020 20:02 UTC |
Furlow Brenda S.SVP - General Counsel
|
SaleCommon Stock | 505 | $272.48 | $137,601.29 |
DisclosureSEC source: 0001562180-20-005109 · primarydocument.xml · nonDerivative · entry 3 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,445 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $271.8500 to $272.8300, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.